Evonik Industries AG has confirmed its 2025 earnings forecast, following a good start to the year. The company continues to expect adjusted EBITDA in the range of €2.0 billion-€2.3 billion, as per Chemweek.
Evonik’s CFO Maike Schuh said earlier today during an analysts’ call that the risks have increased since the company provided its outlook range back in March, but it is still “very much intact and realistic,” because it can confirm all positive factors and assumptions.
“We will deliver high double-digit million additional net savings. We expect lower energy costs from our hedges as well as decreasing spot energy prices on smaller unhedged parts. And our animal nutrition business continues to do better for longer. The methionine market will remain tight also in the second quarter of the year, and demand continues to be very strong,” Schuh said.
The company is expecting a lower global GDP growth for 2025, at only 2.2%, compared with 2.5% two months ago, while foreign exchange is turning from a “tailwind into a headwind,” Schuh added. The direct impact from tariffs is expected to be low, he said.
“It is clear that there are some risks around us and that we cannot fully assess all of them at the moment. Weak customer and end consumer confidence, further escalating trade and tariff tensions or even a global recession are scenarios we have and we do prepare ourselves for,” Schuh said during the call.
Visibility is currently very low, but there are no indications that the situation is getting significantly worse, he noted. EBITDA in April continued in line with the average monthly level of the first quarter across all Evonik’s businesses, he said. “There is no pronounced macro slowdown and no significant drop in volumes or orders visible yet,” he added.
Better than expected pricing trends in the animal nutrition business supported earnings growth in the first quarter of 2025, Evonik said, adding that it expects this trend to continue at least in the second quarter of the year.
Evonik reported a 49% year-over-year increase in first-quarter net profit, to €233 million, while adjusted EBITDA was 7% higher, at €560 million, beating analysts’ consensus estimate of €533 million, provided by S&P Capital IQ. The company’s adjusted EBITDA margin rose 1%, to 14.8%.
Cost discipline and higher sales volumes, up 2% year over year, also supported the increase in first-quarter earnings, Evonik said. Revenue, however, declined 1%, to €3.78 billion, as prices declined by 2%, the company said.
“We had a good start to the year. However, the combination of a looming global trade war and armed conflicts makes planning for the future more uncertain than ever,” said Evonik’s CEO Christian Kullmann.
The company’s specialty additives business recorded a 1% increase in sales, to €923 million, due to slightly higher volumes and positive currency effects, Evonik said. The business’ adjusted EBITDA was 1% higher, at €201 million, while the adjusted EBITDA margin was 21.9%, compared with 21.8%, the prior-year period.
Sales of the company’s nutrition and care business increased 12% year over year, to €1.01 billion, mainly due to higher sales volumes, it said. The business’ adjusted EBITDA improved 35%, to €197 million, while the adjusted EBITDA margin rose 3.4 percentage points compared with the prior-year period, to 19.6%.
Sales of Evonik’s smart materials business were flat year over year, to €1.1 billion, with volumes and selling prices roughly on par with the prior-year quarter, the company said. The business’ adjusted EBITDA was €149 million, 7% down compared with the first quarter of 2024. The adjusted EBITDA margin decreased 1 percentage point, to 13.6%.
mrchub.com